Aggregation of Antibody-Drug Conjugates [poster]

Antibody-Drug Conjugates (ADCs) show much promise as effective therapeutics for cancer and other diseases. However, they often exhibit an increased aggregation propensity compared to their unmodified counterparts due to non-specific interactions arising from attached drug and linker moieties. Light scattering offers multiple techniques for addressing the challenges of formulation screening, and characterizing both aggregates and propensity for aggregation. We present these tools in the context of ADCs and the dependence of aggregation profiles on linker chemistry.